BRCA1 and ovarian carcinoma: The ovarian cancer risk was estimated at 35–46% in BRCA1 carriers and 13–23% in BRCA2 carriers.4 Other studies have estimated these risks to be even higher.5 Given these risks, targeting BRCA pathogenic mutations in breast cancer patients is an attractive strategy for systemic therapy.